Kucera Pharmaceuticals has received a National Institutes of Health research grant to develop potential treatments for treatment of respiratory syncytial virus, or RSV.

The grant is a Phase I Small Business Innovation Research award.

“The Phase I SBIR grant will support the synthesis and evaluation of novel anti-RSV compounds in animal models of RSV,” said Ronald Fleming, chief scientific officer of Kucera who also is the principal investigator of the grant.

RSV is a common cause of bronchiolitis and pneumonia for infants and children.

Kucera: www.kucerapharma.com